Vendor Intelligence Report: Quenna PMQ

Executive summary

Quenna PMQ is a recent peptide storefront with a much older operator trail. The public website appears only in late 2025, while Finnrick testing and outreach activity predate the domain. Corporate and review searches did not verify a legal entity behind the brand, and the same Shanghai address ties Quenna to ZZQ Peptide, a sister-brand lead reinforced by reports of Quenna from ZZQ outreach.

Across 20 Finnrick lab tests, Quenna PMQ recorded 14 passes and 6 failures, for a 70% overall pass rate. The lab record is not a simple never-buy story: Quenna can ship peptide that passes. But the two tested products sit close together in the mid-70s, with Tirzepatide only marginally stronger than Retatrutide; both include complete identity failures, and Retatrutide carries the more severe dosing signal, including a reported 47.5% underdose. Ratings also become less reassuring under stricter grading than the public Purity Focus methodology.

The larger buyer-risk finding is attribution and traceability. The account that promoted Quenna also ran an earlier research-chemical vendor presence listing synthetic cannabinoids, alpha-PVP, designer benzodiazepines and BMK/PMK precursors. Field materials report most Quenna vials lacking labels or batch IDs, while the website retains an Adventure Aura travel template, Mochi Health testimonials, Core Peptides imagery, Chinese coming soon remnants and direct-message ordering.

Regulatory exposure is part of the product-specific read. Quenna is not identified as FDA Green-Listed, and its tested GLP-1 products fall into the same import-alert and CBP seizure environment discussed in the dossier. The full report separates what Quenna has been able to pass from where identity, dose, operator history and import risk make current-lot testing essential.

Inside the full report:

• Per-product pass/fail rates and methodology-divergence charts for Tirzepatide and Retatrutide
• Documented timeline from RCS-quenna’s 2023 forum account to the November 2025 Quenna domain build
• Quenna-ZZQ sister-brand comparison using shared address, contact patterns and forum outreach artifacts
• Website-integrity exhibits covering the travel template, copied testimonials, Core Peptides imagery and Chinese page remnants
• Regulatory analysis of FDA Import Alert 66-80, Green List absence and CBP peptide-seizure context

Risk assessment

• Controlled-substance / RC-vendor background risk — high: Same RCS-quenna/yuanna1818 identity promoted Quenna and, since 2023, offered alpha-PVP, synthetic cannabinoid precursors, designer benzodiazepines and BMK/PMK precursors on Drugbuyersguide.info.
• Tirzepatide quality and identity risk — high: Quenna Tirzepatide has 11 Finnrick tests (8 pass / 3 fail), a 75.39% current rating, and a documented batch Qp022525 that contained no labeled Tirzepatide.
• Retatrutide quality, identity, and dosing risk — high: Quenna Retatrutide has 9 Finnrick tests (6 pass / 3 fail), a 74.32% current rating, a no-Retatrutide batch QPR022526, and a 47.5% underdose event.
• Batch-traceability risk — high: Field materials report most Quenna vials lacking labels or batch IDs, making lot-to-test matching and recalls impractical for Tirzepatide and Retatrutide.
• Website-identity fabrication and brand-confusion risk — high: Quenna uses an unfinished travel template, Mochi Health testimonials, Core Peptides imagery and no documented official-channel or anti-counterfeit verification system.
• Corporate-opacity and sister-brand risk — medium: No verified legal entity was found; Quenna and ZZQ Peptide share the same Shanghai address and community reporting ties the seller persona to ZZQ.
• Regulatory and import-seizure risk — high: Quenna is not FDA Green-Listed, and its GLP-1 products Tirzepatide and Retatrutide fall in the same enforcement category as FDA Import Alert 66-80 and CBP peptide seizures.
• Unsolicited/direct-channel marketing risk — medium: GLP-1 Forum users reported Quenna from ZZQ WhatsApp group additions and repeated solicitations; Quenna routes orders through direct contact rather than a standard checkout flow.